

S.R. Burzynski M.D., Ph.D.
Burzynski Research Institute, INC.
Houston Texas U.S.A.

Dear Dr. Burzynski

Thank you for the interesting information regarding Dr. Green's article appeared in JAMA.

As we recall, we corresponded to Dr. Green once or twice. He sent us a letter asking information on Antineoplaston research and clinical investigation.

We replied and told him that he should wait until we publish the data. And we also told him that we do not think he is going to pick up any biological effect of Antineoplaston A-10 in our study. In this sentence, we liked to say very much that since Dr. Green is not M.D., he will not pick up any biological effect of Antineoplaston A-10 in our study even there is evidence there.

That is what we ment in our letter.

Since we are not native English speackers, he took the meaning different way.

Today we received a letter from Dr. Green again asking reprint of our papers especially on the result of clinical investigation. It looks like he wants to know our result. He said he was told that we published the results of clinical trial in May, we did not published yet, we wonder who told him.


We think you do not have to rebut to this article because NCI will give the straight answer sooner or later from their clinical trial on brain tumors.

Sometimes silence has more power than anything and it is not wise for you to give impression to other scientists that you are fighting all the time. Nobody wants to get involved in such fight.

The best way we think to persuade them is to publish the scientific data in the authorized medical journal, which means the referees are convinced that Antineoplastons are useful. And the referees are usually leaders of this field.

We will publish some case reports indicating that Antineoplastons have been beneficial for the cancer patients and we will report the total result of our clinical pilot study probably by the end of this year. We will publish these papers in popular medical journals.

Please take care of yourself
With best regards



Hideaki Tsuda M.D.

Hiroshi Nara M.D.

Antineoplaston Study Group
Kurume University School of Medicine

8 June 1992